EGI
CBAY

EAM Global Investors’s Cymabay Therapeutics CBAY Stock Holding History

EAM Global Investors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-311,808
Closed -$1.96M – 208
2022
Q4 		$1.96M Buy
+311,808
New +$1.19M 0.5% 78
2020
Q4 		– Sell
-284,534
Closed -$2.06M – 184
2020
Q3 		$2.06M Buy
+284,534
New +$1.52M 0.76% 55
2018
Q3 		– Sell
-66,882
Closed -$898K – 198
2018
Q2 		$898K Sell
66,882
-24,442
-27% -$306K 0.44% 134
2018
Q1 		$1.19M Sell
91,324
-18,678
-17% -$232K 0.61% 70
2017
Q4 		$1.01M Buy
+110,002
New +$940K 0.52% 88

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM Global Investors's CBAY Position: Q1 2023 in Review

EAM Global Investors sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 311,808 shares — an estimated $1.96M sold.

EAM Global Investors first reported a position in CBAY in Q4 2017 and held it in 5 quarters. The position peaked at $2.06M in Q3 2020. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • EAM Global Investors reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 311,808 Cymabay Therapeutics shares in Q1 2023, an estimated $1.96M.
  • EAM Global Investors first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 5 quarters.
  • EAM Global Investors's Cymabay Therapeutics position peaked at $2.06M in Q3 2020.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.